These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8369102)

  • 41. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.
    Uchiyama T; Sakakibara R; Hattori T; Yamanishi T
    Mov Disord; 2003 May; 18(5):573-8. PubMed ID: 12722172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of L-dopa on visual evoked potential in patients with Parkinson's disease.
    Bhaskar PA; Vanchilingam S; Bhaskar EA; Devaprabhu A; Ganesan RA
    Neurology; 1986 Aug; 36(8):1119-21. PubMed ID: 3736880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dopamine-responsive pattern in tremor patients.
    Imbach LL; Sommerauer M; Leuenberger K; Schreglmann SR; Maier O; Uhl M; Gassert R; Baumann CR
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1283-6. PubMed ID: 25260965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Melatonin secretion in patients with Parkinson's disease receiving different-dose levodopa therapy.
    Kataoka H; Saeki K; Kurumatani N; Sugie K; Obayashi K
    Sleep Med; 2020 Nov; 75():309-314. PubMed ID: 32950012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Speech changes in Parkinson's disease during treatment with L-dopa.
    Wolfe VI; Garvin JS; Bacon M; Waldrop W
    J Commun Disord; 1975 Sep; 8(3):271-9. PubMed ID: 802977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
    Paul R; Borah A
    Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism.
    Tohgi H; Takahashi S; Abe T; Utsugisawa K
    Eur Neurol; 2001; 46(1):1-10. PubMed ID: 11455176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Gastric acid secretion and absorption of levodopa in patients with Parkinson's disease--the effect of supplement therapy to gastric acid].
    Yazawa I; Terao Y; Sai I; Hashimoto K; Sakuta M
    Rinsho Shinkeigaku; 1994 Mar; 34(3):264-6. PubMed ID: 8200147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome.
    Garcia-Borreguero D; Larrosa O; Granizo JJ; de la Llave Y; Hening WA
    Sleep; 2004 Jun; 27(4):669-73. PubMed ID: 15283001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Bereitschaftspotential, L-DOPA and Parkinson's disease.
    Dick JP; Cantello R; Buruma O; Gioux M; Benecke R; Day BL; Rothwell JC; Thompson PD; Marsden CD
    Electroencephalogr Clin Neurophysiol; 1987 Mar; 66(3):263-74. PubMed ID: 2434310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tremor and voluntary repetitive movement in Parkinson's disease: comparison before and after L-dopa with positron emission tomography.
    Duffau H; Tzourio N; Caparros-Lefebvre D; Parker F; Mazoyer B
    Exp Brain Res; 1996; 107(3):453-62. PubMed ID: 8821385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical analysis of akinesia.
    Narabayashi H
    J Neural Transm Suppl; 1980; (16):129-36. PubMed ID: 6933217
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nocturnal Melatonin Profiles in Patients with Delayed Sleep-Wake Phase Disorder and Control Sleepers.
    Micic G; Lovato N; Gradisar M; Burgess HJ; Ferguson SA; Kennaway DJ; Lack L
    J Biol Rhythms; 2015 Oct; 30(5):437-48. PubMed ID: 26149168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The circadian rhythm of melatonin in hypothyroidism and hyperthyroidism.
    Soszyński P; Zgliczyński S; Pucilowska J
    Acta Endocrinol (Copenh); 1988 Oct; 119(2):240-4. PubMed ID: 3176816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease.
    Bolitho SJ; Naismith SL; Rajaratnam SM; Grunstein RR; Hodges JR; Terpening Z; Rogers N; Lewis SJ
    Sleep Med; 2014 Mar; 15(3):342-7. PubMed ID: 24529544
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.